A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]
In a small phase 2 study presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), the novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), showed promising anti-cancer activity in combination with cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) that had been previously treated. Kidney cancers develop […]
Results of a retrospective study presented during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) looked at the effect of immune checkpoint inhibitors (immunotherapy, e.g. nivolumab, ipilimumab, pembrolizumab) on the survival of patients with metastatic non-clear cell renal cell carcinoma (RCC) compared to targeted therapy with vascular endothelial growth factor (VEGF) […]
Long-term follow-up data from the CheckMate-214 study of the nivolumab plus ipilimumab combination in untreated, advanced clear cell kidney cancer patients were presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. Patients were followed for at least 4 years after treatment with nivolumab plus ipilimumab […]
Data from the CheckMate-920 study on the safety and effectiveness of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) was presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. CheckMate-920 is a community-based, phase IIIb/IV clinical trial of nivolumab plus […]
A recent study published in JAMA Network Open looked at the data from over 10,000 renal cell carcinoma (RCC) patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and reported on the sites of metastases for three of the RCC subtypes and their survival outcomes. Metastases from clear cell RCC (9252 patients, 92%) […]
Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are prevented from getting to the brain by a membrane called the blood-brain barrier. In this study, the results of which will be presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) […]
The past couple of years has seen a number of combination therapies for the first-line treatment of advanced/metastatic renal cell carcinoma (RCC) become available. At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco this week, ongoing results from the phase 3 CheckMate-9ER clinical trial with the nivolumab plus cabozantinib […]
The recent phase II KEYNOTE-427 study investigated the efficacy and safety of pembrolizumab in patients with untreated advanced clear cell renal cell carcinoma (RCC) and non-clear cell RCC. Pembrolizumab is a type of immunotherapy (an immune checkpoint inhibitor called a programmed death 1 inhibitor, PD-1), which has been shown to be effective in untreated patients […]
A recent study published in the International Journal of Clinical Oncology looked at the distribution of metastases in patients with metastatic renal cell carcinoma (RCC) according to age and sex. 9,607 patients with metastatic RCC were identified from the National Inpatient Sample database (2008-2015) and analysed for site of metastases according to age and sex. […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
